DempoChem Logo
  1. HomeHome
  2. /ProductsProducts
  3. /Bioactive CompoundsBioactive Compounds
  4. /GPCR & G Protein TargetsGPCR & G Protein Targets
  5. /Cholecystokinin ReceptorCholecystokinin Receptor
  6. /DevazepideDevazepide
Chemical structure of CAS 103420-77-5

Devazepide

In Stock•Starting at $236 for 5 mg•Purity ≥ 98%
CAS No.103420-77-5
MDL No.MFCD00864500
MFC25H20N4O2
MW408.50
InChI KeyNFHRQQKPEBFUJK-HSZRJFAPSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT→

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
5 mg98%(HPLC)$236In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

Devazepide is an indolecarboxamide formed by the formal condensation of the carboxy group of indole-2-carboxylic acid with the exocyclic amino group of (3S)-3-amino-1-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one. It is a cholecystokinin antagonist used in the treatment of gastrointestinal disorders. It functions as an antineoplastic agent, gastrointestinal drug, apoptosis inducer, and cholecystokinin antagonist. It is classified as a 1,4-benzodiazepinone and an indolecarboxamide.

CAS No.103420-77-5
Product NameDevazepide

Associated Conditions

gastrointestinal disease
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Cholecystokinin-8 attenuates methamphetamine-induced inflammatory activation of microglial cells through CCK2 receptor.

Neurotoxicology • Vol. 81 • 2020
PMID: 32916201DOI: 10.1016/j.neuro.2020.09.001

Anorexia induction by the trichothecene deoxynivalenol (vomitoxin) is mediated by the release of the gut satiety hormone peptide YY.

Toxicological sciences : an official journal of the Society of Toxicology • Vol. 130, Issue 2 • 2012
PMID: 22903826PMC: PMC3621367DOI: 10.1093/toxsci/kfs255

New anthranilic acid based antagonists with high affinity and selectivity for the human cholecystokinin receptor 1 (hCCK1-R).

Journal of medicinal chemistry • Vol. 54, Issue 16 • 2011
PMID: 21728335DOI: 10.1021/jm200438b

Role of CCK1 and Y2 receptors in activation of hindbrain neurons induced by intragastric administration of bitter taste receptor ligands.

American journal of physiology. Regulatory, integrative and comparative physiology • Vol. 294, Issue 1 • 2008
PMID: 18003792DOI: 10.1152/ajpregu.00675.2007

Documentation

Your Partner for
Complex Chemistry
logo
  • About Us
  • Perspectives
  • Products
  • Contact
  • Preclinical Development
  • Technologies
  • Custom Synthesis
Ready to start your project?

Provide your target molecule or project specifications to align on a tailored development and scale-up pathway with our scientific team.

START A PROJECT
Westerstraat 10, 3016 DH, Rotterdam, The Netherlands
Westerstraat 10, 3016 DH, Rotterdam, The Netherlands
logo

All products are supplied strictly for research and development use only and are not intended for human or veterinary administration, diagnostic use, or therapeutic use. Preclinical and related services are provided solely for research and development purposes and do not constitute clinical diagnosis, treatment, or veterinary care.

©2026 DempoChem. All Rights Reserved.
DHLFedExUPSPostNL
CLIENT PORTAL|TERMS AND CONDITIONS|PRIVACY POLICY|
  • Products
    • CDMO Compounds
    • API & Candidates
  • Services
    CDMO & Manufacturing
    • Custom Synthesis
    • Process Development
    • Lab To Pilot
    • Commercialization
    • Generic APIs
    CRO
    • Preclinical
    • Pharmacology & Efficacy
    • DMPK & Bioanalysis
    • Toxicology & Safety
    • Disease Models
    Technologies
    • High-Potent
    • Chiral Synthesis
    • Cloud Synthesis
    • Fermentation
    • Flow Chemistry
    • Biocatalysis
    Support
    • Regulatory Support
    • Supply Chain Solutions
  • About
  • Perspectives
  • Contact